Sarepta Therapeutics

Cambridge,  MA 
United States
  • Booth: 1237

Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s programs span across several therapeutic modalities, including RNA, gene therapy and gene editing.  Sarepta is proud to support AAN 2019.

 Additional Info

First Time Exhibitor
For Technical Support with this webpage, please contact support.